Characterization of SARS-CoV-2 RBD IgG humoral response using Single Molecule Counting (SMC™) technology

Tue23  Feb02:35pm(15 mins)
Where:
Conference Room 2
Speaker:
Sponsor:
Merck
Merck
 Alex Ko

Abstract

: Immunoassay-based serology techniques play key roles in many SARS-CoV-2 research programs due to their ability to identify and characterize the immune response of individuals already infected by the virus through analysis of biomarkers such as immunoglobulins (Ig). However, the limited sensitivity and resolution offered by traditional assay platforms and their serology assays can leave unanswered crucial research questions. We harnessed the power of the Single Molecule Counting (SMC™) ultrasensitive immunoassay platform for the development of new products to address the scientific community’s needs including identifying low level SARS-CoV-2 mediated antibody response and resolving subtle differences in humoral immunity among individuals. The new SMC™ SARS-CoV-2 RBD IgG kit can be used by researchers to accurately understand the extent of SARS-CoV-2 infection in society, thoroughly profile immune responses after vaccine challenge, and understand heterogeneous responses to infection among individuals and subpopulations.’
To view the video assoicated with this lecture click here
Youtube

Hosted By

ELRIG
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Login
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021